

Phospho-EGFR (Y1110) Antibody

Rabbit mAb

Catalog # AP90599

Product Information

Application	WB, IF, ICC, IP
Primary Accession	P00533
Reactivity	Human
Clonality	Monoclonal
Other Names	EC 2.7.10.1; ERBB1; Epidermal growth factor receptor precursor; Receptor protein-tyrosine kinase ErbB-1; kinase EGFR;
Isotype	Rabbit IgG
Host	Rabbit
Calculated MW	134277

Additional Information

Dilution	WB 1:500~1:2000 ICC/IF 1:50~1:200 IP 1:50
Purification	Affinity-chromatography
Immunogen	A synthesized peptide derived from human EGFR Full-length sequence 1210aa around the phosphorylation site of Tyrosine 1110
Description	The epidermal growth factor (EGF) receptor is a transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling, internalization, and lysosomal degradation. Phospho-EGF Receptor (Tyr1086) Antibody is directed against a previously unpublished EGF receptor phosphorylation site at Tyr1086, Phosphorylation of EGF receptor at Tyr1086 was observed in select carcinoma cell lines and in tumors.
Storage Condition and Buffer	Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle.

Protein Information

Name	EGFR (HGNC:3236)
Synonyms	ERBB, ERBB1, HER1
Function	Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed: 10805725 , PubMed: 27153536 , PubMed: 2790960 , PubMed: 35538033). Known ligands include EGF, TGFA/TGF- alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed: 12297049 , PubMed: 15611079 , PubMed: 17909029 , PubMed: 20837704 , PubMed: 27153536 , PubMed: 2790960 , PubMed: 7679104 , PubMed: 8144591 , PubMed: 9419975). Ligand binding triggers receptor homo-

and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:[27153536](#)). May also activate the NF-kappa-B signaling cascade (PubMed:[11116146](#)). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:[11602604](#)). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:[11483589](#)). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:[20462955](#)). Plays a role in enhancing learning and memory performance (By similarity). Plays a role in mammalian pain signaling (long-lasting hypersensitivity) (By similarity).


Cellular Location

Cell membrane; Single-pass type I membrane protein. Endoplasmic reticulum membrane; Single-pass type I membrane protein Golgi apparatus membrane; Single-pass type I membrane protein. Nucleus membrane; Single-pass type I membrane protein. Endosome. Endosome membrane. Nucleus. Note=In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:17909029, PubMed:20674546). Endocytosed upon activation by ligand (PubMed:17182860, PubMed:17909029, PubMed:27153536, PubMed:2790960). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055)

Tissue Location

Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Images



Western blot analysis of Phospho-EGFR (Y1086) expression in (1) A431 cell lysate; (2) A431 cell lysate treated with EGF.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.